CG
GTHX

Cutler Group’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Cutler Group’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,700
Closed -$19K – 6301
2021
Q3 		$19K Buy
1,700
+100
+6% +$1.63K ﹤0.01% 3403
2021
Q2 		$8K Hold
1,600
– – ﹤0.01% 4131
2021
Q1 		$10K Buy
+1,600
New +$37.2K ﹤0.01% 3839
2020
Q4 		– Sell
-2,500
Closed -$8K – 5649
2020
Q3 		$8K Buy
+2,500
New +$41.3K ﹤0.01% 3198

Other funds holding GTHX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Cutler Group's GTHX Position: Q4 2022 in Review

Cutler Group sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2022, closing a stake of 300 shares — an estimated $3K sold.

Cutler Group first reported a position in GTHX in Q4 2018 and held it in 15 quarters. The position peaked at $71K in Q4 2019. 116 funds tracked by Wall St. Rank hold GTHX as of Q4 2022.

  • Cutler Group reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Cutler Group sold 300 G1 Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $3K.
  • Cutler Group first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2018 and held it in 15 quarters.
  • Cutler Group's G1 Therapeutics, Inc. Common Stock position peaked at $71K in Q4 2019.
  • 116 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.